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Although elevated cancer risk has been
demonstrated in people exposed to arsenic in
drinking water, the data generally cannot 
distinguish between various possible dose–
response relationships, such as linear, qua-
dratic, or hockey stick (Buchet and Lison
2000). However, studies of skin or bladder
cancer among persons consuming arsenic-
contaminated drinking water in Taiwan were
consistent with linearity, although other
forms could not be ruled out (Brown et al.
1989, 1997; Chiou et al. 2001). Lung cancer
in smelter workers was consistent with linear
when analyzed according to the excess
mortality approach but not when analyzed
according to the standard mortality approach
(Viren and Silvers 1999).
In other studies, dose–response tended to
be hockey stick shaped at low levels of arsenic
(~ < 100 ppb) in drinking water for skin can-
cer and for non-neoplastic end points, such as
hyperpigmentation and keratosis (Tucker
et al. 2001). Males were considerably more
susceptible than females, and low body
weight, presumably a result of poor nutrition,
was predisposing (Guha Mazumder et al.
1998). Although solar keratosis is a benign
neoplastic condition thought by some to be a
precursor of squamous cell carcinomas, no
direct linkage was apparent in these studies.
Overall, the human data are not yet sufﬁcient
to contest the low-dose linearity default form
of the dose–response relationship for cancer
induction by arsenite (Huff et al. 1998).
Numerous ideas have been put forward
to explain arsenic’s carcinogenic activity
(Abernathy et al. 1999; Corsini et al. 1999;
Germolec et al. 1997; Rossman 2003;
Rossman et al. 2002; Simeonova and Luster
2000; Yager and Wiencke 1993, 1997).
Possible mechanisms include reduced DNA
repair, altered DNA methylation, increased
growth factors, enhanced cell proliferation,
induction of gene amplification (an indica-
tion of genomic instability), and suppressed
p53 expression leading to faulty DNA dam-
age signaling (which also affects repair). In
support of the latter, it was recently found that
arsenite prevented S-phase arrest in human
lung tumor cells irradiated with ultraviolet C
radiation (UV-C; Hartwig et al. 2002).
Although proliferation is a requisite of skin
tumor promotion (Schlatterer et al. 2000),
work with transgenic mice indicates that
arsenic has little or no tumor-promoting
activity (Germolec et al. 1998).
Arsenic is carcinogenic without binding
to DNA, although at higher doses deletion
mutations, typically associated with oxidative
DNA damage, occur (Bau et al. 2002; Hei
et al. 1998). One of the most puzzling aspects
of arsenic carcinogenesis has been the high
susceptibility of humans and the seeming
refractoriness of laboratory animals to arsenic
in drinking water (National Research Council
1999). A clue to the mechanism of arsenite’s
carcinogenic action was derived from in vitro
mutagenesis studies with Chinese hamster
fibroblasts (V-79 cells). Arsenite, not muta-
genic by itself, enhanced the mutagenicity
of carcinogens, such as ultraviolet radiation
(UVR) and methylnitrosourea (Li and
Rossman 1989b; Rossman 1989). This so-
called co-mutagenic effect of arsenite was
based on an inhibition of the ligation step in
base excision repair (Li and Rossman 1989a,
1991), although direct inactivation of the lig-
ase itself was ruled out (Rossman 1981; Hu
et al. 1998).
Human osteogenic sarcoma cells exhibited
delayed mutagenesis after many generations
of exposure to extremely low concentrations
(< 0.1 µM) of arsenite (Mure et al. 2003).
Studies with normal human ﬁbroblasts in vitro
have shown that arsenite at low concentrations
(0.1 µM) interferes with p53 signaling and
causes up-regulation of cyclin D1 (Vogt and
Rossman 2001). The latter ﬁnding raises the
possibility that arsenite may reverse the
p53-dependent proliferation blockage typically
associated with DNA-damaging agents.
Other possible mechanisms exist. For
example, mouse Hepa-1 cells exposed to
benzo[a]pyrene in vitro exhibited an 18-fold
increase of DNA adducts in the presence of
arsenite compared with no arsenite. The rate
of adduct removal was not affected, implying
that arsenite acted before adduct removal in
this system (Maier et al. 2002).
The present study was designed to establish
the shape of the dose–response relationship
for cancer enhancement in a new mouse skin
model using arsenite in drinking water in
combination with chronic topical UVR expo-
sures (Rossman et al. 2001).
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Arsenic-Induced Enhancement of Ultraviolet Radiation Carcinogenesis in
Mouse Skin: A Dose–Response Study
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The present study was designed to establish the form of the dose–response relationship for dietary
sodium arsenite as a co-carcinogen with ultraviolet radiation (UVR) in a mouse skin model.
Hairless mice (strain Skh1) were fed sodium arsenite continuously in drinking water starting at
21 days of age at concentrations of 0.0, 1.25, 2.5, 5.0, and 10 mg/L. At 42 days of age, solar spec-
trum UVR exposures were applied three times weekly to the dorsal skin at 1.0 kJ/m2 per exposure
until the experiment ended at 182 days. Untreated mice and mice fed only arsenite developed no
tumors. In the remaining groups a total of 322 locally invasive squamous carcinomas occurred.
The carcinoma yield in mice exposed only to UVR was 2.4 ± 0.5 cancers/mouse at 182 days.
Dietary arsenite markedly enhanced the UVR-induced cancer yield in a pattern consistent with
linearity up to a peak of 11.1 ± 1.0 cancers/mouse at 5.0 mg/L arsenite, representing a peak
enhancement ratio of 4.63 ± 1.05. A decline occurred to 6.8 ± 0.8 cancers/mouse at 10.0 mg/L
arsenite. New cancer rates exhibited a consistent-with-linear dependence on time beginning after
initial cancer-free intervals ranging between 88 and 95 days. Epidermal hyperplasia was elevated
by arsenite alone and UVR alone and was greater than additive for the combined exposures as
were growth rates of the cancers. These results demonstrate the usefulness of a new animal model
for studying the carcinogenic action of dietary arsenite on skin exposed to UVR and should con-
tribute to understanding how to make use of animal data for assessment of human cancer risks in
tissues exposed to mixtures of carcinogens and cancer-enhancing agents. Key words: arsenic, arsen-
ite, cancer, hairless, mouse, radiation, skin, ultraviolet, UV. Environ Health Perspect 112:599–603
(2004). doi:10.1289/ehp.6655 available via http://dx.doi.org/ [Online 6 January 2004]Materials and Methods
The protocol combined indeﬁnite exposure to
arsenic in drinking water with concomitant
exposure to intermittent, topical UVR. The
Hairless mice (strain Skh1) were fed sodium
arsenite at various concentrations in drinking
water starting at 21 days of age, as shown in
Table 1. At 42 days of age (defined as time
zero), the irradiations began on a Monday–
Wednesday–Friday schedule at a dose of
1.0 kJ/m2 UVR per exposure (solar spectrum).
The UVR source was a bank of four ﬂuores-
cent tubes (FS 20) mounted in parallel 15 cm
apart. The mice were irradiated 30 cm below
the source at a rate of 0.2 kJ/m2/min. The dose
was estimated to be about one-fourth the mini-
mal erythemic dose for these mice. The mice
were observed periodically for the presence
of skin lesions, which were counted at each
observation. The number of new tumors was
obtained by subtracting the count at the previ-
ous observation. At the end of the experiment
a large sample of tumors were examined histo-
logically. More than 95% were diagnosed as
squamous cell carcinomas.
Daily new cancer rates (R) in units of can-
cers per mouse per day were estimated for each
interval by dividing the number of new tumors
by the average number of mice alive and the
length of the interval in days and were plotted
at the midpoint of the intervals. Cumulative
cancer yields (CY) were estimated by progres-
sively summing the product of the rates and
interval length in days. Standard deviations
were estimated from the square root of the
total cancers by assuming a Poisson distribu-
tion of cancers among mice. Linear regression
analysis of the estimated new cancer rates was
used to evaluate the parameters in Equation 1:
the slope B, the length of the cancer-free inter-
val t0, and their respective standard deviations.
Based on these values, cancer yields were calcu-
lated from Equation 2 and compared with the
estimates of CY calculated as described above.
Equation 2 is the time integral of Equation 1,
and Equation 3 is 1 minus the ﬁrst term in the
Poisson distribution.
R = new cancer rate = B (t – t0) [1]
CY = cancer yield = (1/2) B (t – t0)2 [2]
PC = % with cancer = 100 (1 – e–CY) [3]
Results
Figure 1 shows mice selected randomly at
182 days from the UV-only group (Figure 1A)
and the UV plus 1.25 mg/L group (Figure 1B).
A lesion diameter of ≥ 2.0 mm was chosen as
the criterion for distinguishing tumors from
suspicious lesions. The arsenite affected both
the number and size of the tumors, and even
greater effects were noted at higher arsenite
concentrations. Histologically, the tumors
were squamous cell carcinomas as typically
seen in mouse skin exposed to carcinogens
(Rossman et al. 2001). Of the 322 cancers
that were seen, 45 (~14%) showed especially
rapid growth, whereas the remainder exhib-
ited a distribution of growth rates. Some of
the latter became almost indolent, reaching
growth stasis at about 3–5 mm diameter but
were nevertheless histologically distinguishable
from papillomas and consistently showed local
invasion.
Estimates of new cancer rates (cancers per
mouse per day) in Figure 2 show typical vari-
ability of rate data but are fitted reasonably
well with regression lines that extrapolate to
an average time intercept of 93.6 ± 6.1 days
(Table 1). The group receiving only UVR
departed from the general upward trend of
rate versus time in that after reaching a peak of
0.086 at 150.5 days, a decline to 0.029
was seen at the final two time points. A rate
decrease after a peak cannot be accommodated
by Equations 1 and 2, which necessitated not
using the ﬁnal time point. Justiﬁcation for this
discard is based on the observations that a) the
UVR-only group developed the fewest cancers
and would be subject to the greatest random
ﬂuctuations and b) a second experiment with a
slightly higher UVR dose failed to show a
similar rate decrease.
Overall, these data indicate that arsenite
enhanced the yield of UVR-induced cancers
in a multiplicative way with little effect on the
temporal onsets; that is, the main effect of the
arsenite was to increase the slope, B. A multi-
plicative effect is not unexpected for an
enhancing agent that lacks carcinogenic activ-
ity of its own. Both the estimated and calcu-
lated yields are shown in Figure 3—estimated
yields as data points and calculated yields as
smooth curves based on Equation 2.
Although induced cancers in animals
seem to be independent events, it is difficult
to be sure that later cancers are not somehow
inﬂuenced by the presence of earlier ones. One
approach to assessing this problem is to use a
Kaplan-Meier calculation that relies only on
the ﬁrst tumor on each animal, which by deﬁn-
ition cannot be inﬂuenced by earlier tumors.
The results of these calculations are shown in
Figure 4. The relative lack of a dose dependence
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Table 1. Summary of experimental and calculated cancer yields and tumor-free intervals.
Experimental yield ± SD Calculated yield ± SD  Slope Cancer-free
UV (kJ/m2)/ at 182 days at 182 days (cancers/ interval
arsenite (mg/L) (cancers/animal) (cancers/animal) mouse/day2) (days)
1.0/0.00 2.40 ± 0.48 3.43 ± 1.94 0.00109279 103.4
1.0/1.25 5.40 ± 0.73 5.45 ± 0.79 0.00132573 91.3
1.0/2.50 7.21 ± 0.89 7.24 ± 1.35 0.00192710 95.3
1.0/5.00 11.10 ± 1.05 11.06 ± 1.25 0.00247784 87.5
1.0/10.0 6.80 ± 0.82 7.22 ± 2.38 0.00173550 90.8
93.7a
1.7/0.00 3.47 ± 0.48 4.17 ± 1.09 0.00102334 91.8
1.7/10.0 9.56 ± 0.85 11.23 ± 2.62 0.00156513 62.2
77.0a
aThese numbers are averages of those preceding.
Figure 1. Typical cancer distributions in mice from (A) the UV-only group and (B) mice from the UV plus
1.25 mg/L arsenite group. Based on 2.0 mm diameter, there are ﬁve tumors in (A) and 14 tumors in (B). Even
greater numbers of suspicious lesions are present, although quantitation is difﬁcult on the photographs. Some
suspicious lesions exhibit a growth burst into the tumor range within 2 weeks after cessation of UV exposures.of t0 (time intercepts) in Figure 2 reinforces the
conclusion that the small temporal displace-
ments are probably mostly associated with slope
differences, not displacements along the time
axis (t0 values shown in Table 1). In the UVR-
only group, 50% cancer incidence occurred at
140 days, whereas in the highest response
group (UVR plus 5.0 mg/L), 50% incidence
occurred at 109 days. In the 1.25, 2.50, and
10 mg/L groups (the latter not shown for clar-
ity), the 50% incidence values were clustered
near 120 days. The smooth lines in Figures 3
and 4 constitute families of curves. The close-
ness of the data points to the lines implies that
reasonable estimates of slope B and time inter-
cept t0 can be derived from linear regression
analysis of new cancer rates, despite the inher-
ent variability of the rates themselves.
The dose–response relationship of squa-
mous cell carcinoma yield as a function of arsen-
ite concentration is shown in Figures 5 and 6,
where the data are cancer yields expressed as
cancers per mouse at 182 days versus arsenite
concentration. The cancer yield was increased
for all arsenite concentrations, and the peak
enhancement as a ratio of yield for arsenite
plus UVR versus UVR alone occurred at a
concentration of 5.0 mg/L and represented a
peak enhancement ratio of 4.63 ± 1.05. As
the number and size of the cancers increase,
mergers occur more frequently and under-
counting becomes more likely. More than
10 cancers on a single animal generally could
not be enumerated accurately.
Data from the ascending portion of
Figure 5 are shown replotted in Figure 6 along
with a regression analysis that shows 95% con-
ﬁdence interval (CI). The error bars were based
on the square root of the total cancer counts by
assuming a random distribution of cancers
among the mice. The random assumption is
predicated on uniform susceptibility from
animal to animal and no interaction between
multiple cancers on the same animal. The
responses for estimated and calculated cancer
yields are close, as can be seen in Table 1.
Data from a previously reported experi-
ment and data from the present experiment
are combined to show how cancer induction
was altered as the UVR dose changed.
Increasing the UVR dose by 1.70-fold
increased the cancer yield by 1.45-fold, and
the tumor-free interval decreased from
103.4 days to 91.8 days. A greater reduction
in t0 was seen for UVR with the arsenite, from
90.8 days to 62.2 days (Table 1). The arsenite
enhancement at 10 mg/L was about the same
for both UVR doses, averaging 2.79-fold.
At the end of the experiment, the UVR
exposures were stopped and the arsenite was
continued for an extra 2 weeks. Surprisingly,
the growth rate of many of the cancers accel-
erated during this time, as if the UVR were
retarding their growth. This makes sense
because UVR is cytotoxic and would easily
penetrate small cancers to a depth of a few
millimeters.
Epidermal hyperplasia was measured
on histologic preparations of skin samples
obtained from the mice undergoing carcino-
genesis testing and is shown in Figure 7.
The sampling was performed by biopsy on
day 183, 1 day after the ﬁnal UVR exposure.
Epidermal hyperplasia was seen in all groups
that received either dietary arsenite or UVR.
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Figure 2. New cancer rates (R) after treatment with
arsenite as a function of time showing linear
regressions. The rate estimates are plotted at the
midpoint of the observation intervals. Linear
regression analysis was used to estimate the slope
B, and the cancer-free interval t0, and their respec-
tive SDs based on Equation 1. The highest arsenite
concentration (10 mg/L) was omitted for clarity.
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Figure 3. Cancer yield as a function of time for the
various doses of arsenite (1.0 kJ/m2 UVR). The
points are estimated yield data, and the smooth
curves were derived by plugging values for slope B
and cancer-free interval t0 into Equation 2.
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Figure 4. Kaplan-Meier analysis showing the
percentage of mice with one or more cancers after
treatment with arsenite. Estimates are shown as
data points, whereas the smooth curves were
derived by plugging values for B and t0 into Equation
3. Each data point represents one mouse; there were
10 mice at each experimental group. UVR = 1.0 kJ/m2
3 times weekly.
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Figure 5. Dose–response data for estimated cancer
yields at 182 days by the combination of 1.0 kJ/m2
three times weekly and various concentrations of
sodium arsenite continuously in drinking water
showing the enhancement of the cancer yield by
sodium arsenite. Error bars were derived from the
square root of the total number of cancers.
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Figure 6. The ascending segment of the dose–
response data in Figure 5 showing the enhancement
of the cancer yield by sodium arsenite. A linear
regression with 95% CIs is shown ﬁtted to the data.
The error bars were derived from the square roots
of the total number of cancers. UVR = 1.0 kJ/m2 3
times weekly.
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Figure 7. Epidermal hyperplasia in various treat-
ment groups relative to no-treatment controls. The
ordinate is the ratio of treated to control cell counts.
Because the control epidermis is just a little more
than one cell thick, the numbers are an approxi-
mate measure of the number of cell layers in the
hyperplastic epidermis.
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UVR + As (10 mg/L)In mice receiving both agents, the hyperplasia
was more than additive and often showed
nonuniformity suggestive of early, microscopic
neoplasms (Vega et al. 2001).
Discussion
Work with in vitro cell lines indicates that
cyclin D1 is a key regulatory protein in con-
trolling cell proliferation in several different
cell types (Hunter and Pines 1994). Vogt and
Rossman (2001) have reported that arsenite
increases cyclin D1 expression in human
fibroblasts. Arsenite may also activate signal
transduction pathways upstream of cyclin D1
(Germolec et al. 1998; Simeonova and Luster
2000). Huang et al. (2001) reported that arsen-
ite induces extracellular regulated kinase (ERK)
activation through MAP kinase 6/p38–depen-
dent pathways. Both arsenite and arsenate acti-
vated NFκB in mouse epidermal JB6 Cl41
cells but not in 30.7b cells, which are known
to have low levels of ERKs, suggesting that
ERK activation is involved in NFκB activation
by arsenite (Huang et al. 2001).
Combined exposure of cells to arsenite
and ionizing radiation showed that increased
p53-dependent p21 expression, normally a
block to cell cycle progression after DNA
damage, was deﬁcient and likely led to faulty
DNA repair (Vogt and Rossman 2001). Many
researchers have found that exposure of cells to
nontoxic levels of arsenite enhances prolifera-
tion signaling (Barchowsky et al. 1999; Chen
et al. 2001; Germolec et al. 1997, 1998; Vogt
and Rossman 2001). The absence of normal
p53 functioning coupled with growth stimula-
tion likely contributes to defective DNA repair
as well.
The dose–response relationship shown in
Figure 5 is not unlike shapes seen for carcino-
gens in general—an initial increase up to a peak
and then a decline at higher doses. Usually the
decline is ascribed to the carcinogen’s cytotoxic
properties, which predominate over neoplastic
effects at higher doses. However, no direct evi-
dence of cytotoxicity was discernible in tissue
sections taken 1 day after the ﬁnal UVR expo-
sure. For the concentration range from 0 to
5 mg/L arsenite in drinking water, the cancer
enhancement was fitted quite well with a
straight line.
It was surprising that arsenite caused equiv-
alent levels of epidermal hyperplasia indepen-
dent of concentration. Persistent hyperplasia is
a hallmark of tumor promotion in mouse
skin; however, others have shown with trans-
genically initiated mice that arsenite lacks
even a hint of tumor-promoting activity,
meaning that the hyperplasia was not likely
part of a tumor promotion process (Germolec
et al. 1998).
One hypothesis to explain the basis for
the enhancing effect of arsenite on UVR
carcinogenesis may involve a reversal of 
UVR-induced proliferative blockage (Hartwig
et al. 2002). Cell cycle blockage is critical for
preventing proliferation-dependent conversion
of primary DNA damage to mutations and
provides time for excision repair to remove
much of the damage (Kaufmann 1995).
Skin epithelial cells exposed to long-term,
intermittent UVR and dietary arsenite are
probably experiencing a balance between
simultaneous tendencies toward decreased and
increased proliferation. UVR blocks prolif-
eration as a result of DNA damage, whereas
arsenite continuously stimulates proliferation,
through the down-regulation of p21 and the
up-regulation of the cyclin D1 pathway. The
dose–response relationship for arsenite-induced
cancer enhancement may depend on how
effectively proliferative stimulation overcomes
proliferative blockage.
The results reported here are the first
demonstration of a linear relationship between
arsenite concentration in drinking water and
enhancement of the yield of squamous cell
carcinomas in UVR-exposed mouse skin.
The lowest concentration of arsenite used
(1.25 mg/L) equals 721 µg/L arsenic, which is
about 60 times the current allowable level
(10 µg/L) in drinking water in the United
States and is about 50% of the highest concen-
trations (~1,300 µg/L) found in Nevada drink-
ing water (Warner et al. 1994) and about 20%
of the highest concentrations (~3,400 µg/L)
found in drinking water in the West Bengal
region of India (Guha Mazumder et al. 1998).
Arsenic-induced enhancement of carcinogene-
sis in the hairless mouse skin is one of the few
instances where positive carcinogenicity in
laboratory animals occurs at doses well within
the range of human exposures. The results
reported here are consistent with theoretical
approaches that support a linear relationship
between arsenite dose and cancer incidence in
UV-exposed mouse skin. However, the quanti-
tative application of the mouse data to humans
ingesting high arsenite water is still fraught
with difﬁculties related to species response dif-
ferences. Although the arsenite-induced cancer
enhancement in mouse skin was relatively
independent of the UVR dose, the species
dependence of this enhancement is unknown
and could only be guessed for human skin.
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